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INTRODUCTION
Japanese hop, Humulus japonicus, is a major cause of autumn 
pollinosis in East Asia, including China, Japan, and Korea.1 This 
highly allergenic plant is a fast-growing, prickly, invasive twin-
ing bine that smothers whatever it can climb. It is primarily a 
weed of pastures, hayfields, and other non-crop areas. This in-
vasive species was added to the European and Mediterranean 
Plant Protection Organization (EPPO) Alert list in 2007 (www.
eppo.int) and was also listed as an invasive alien plant in 2012 
(www.invasive.org), as it began to invade European countries, 
Greenland, Canada, and the United States (Virginia, Tennessee, 
North Carolina, and West Virginia). This wind-pollinated plant 
produces a large amount of pollen,2 which is abundant in the at-
mosphere during the autumn.3,4  Thus, Japanese hop could be a 
major cause of pollinosis not only in East Asia but also in Euro-
pean and American countries in the near future unless its inva-
sion is adequately controlled. In a study conducted on 812 pa-
tients visiting a specialized clinic in Seoul between 1984 and 
1987, 15.9% were found to be sensitized to Japanese hop.5 Fur-
thermore, the sensitization rate of Japanese hop in the southern 
part of Gyeonggi Province in Korea is reported to have increased 
gradually from 7.1% in 1999 to 8.0% in 2005 and then to 9.6% in 
2008.6
Mugwort is another major cause of autumn pollinosis in Asia. 
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Japanese Hop and Mugwort Standardization
In a multicenter study, 9.6% of 2554 Korean respiratory allergy 
subjects enrolled in 2001 were positive for mugwort allergy 
based on a skin prick test.7 However, in a recent study, a differ-
ence in the sensitivity to mugwort was reported between skin 
prick (13.6%) and ImmunoCAP (22.9%) tests, implying the 
need for further standardization for better diagnosis.8
Standardization of allergen extract is essential for the devel-
opment of diagnostic and immunotherapy reagents for respira-
tory allergic diseases.9 However, many commercial pollen ex-
tracts are not standardized. Non-standardized extracts are 
labeled on the basis of protein nitrogen unit (PNU) or weight of 
source material per volume of buffer used for the allergen ex-
traction (w/v). A target maintenance dose of 0.5 mL of 1:100 or 
1:200 w/v was suggested for immunotherapy.10
Difference in allergen composition among commercial mug-
wort extracts have been reported11 despite descriptions of prep-
aration using a reference extract.12 Geographical differences 
among plant flora may influence the sensitization profiles and 
allergic responses. Artemisia princeps is known to be the domi-
nant species in Korea.13 However, immunoglobulin E (IgE) re-
active components from six different species (A. vulgaris, A. sc-
roparia, A. princeps, A. tridentate, A. anuua, and A. campestris) 
were found to be very similar and highly cross-reactive,14 a find-
ing that was reproduced by Katial, et al.15 These results suggest 
that a pollen extract from a single species is sufficient for diag-
nosis and treatment of mugwort, sagebrush, and wormwood 
allergies. In Korea, most of the mugwort-sensitized subjects 
were found to be co-sensitized to chrysanthemum and dande-
lion, which belong to the family Compositae (Asteraceae), and 
extensive cross-allergenicity among them was also described.16
Allergen extracts have been standardized not only by deter-
mining biological potency of the extract but also by measuring 
the concentrations of major allergens.17 However, the major al-
lergen of Japanese hop has not been characterized. Profilin was 
reported to be a major allergen of Japanese hop from China.18 
However, this was not the case in Korea.19 In this study, we pre-
pared the Japanese hop and mugwort pollen extracts using a 
standardized method and estimated the potency for use as a 
reference standard. Importantly, this was the first report on the 
bioequivalent allergy unit (BAU) of Japanese hop and mugwort 
pollen extract estimated via intradermal skin test.20
MATERIALS AND METHODS
Allergen extracts
A. vulgaris pollen was purchased from Allergon (Angelholm, 
Sweden). Japanese hop pollen was collected from fields in 
Seoul in September 2011. Pollens were defatted three times 
with ethyl ether. For allergen extraction, 1:4 (w/v) phosphate 
buffered saline (pH 7.4) was added and stirred for 48 hours at 
4°C. The extract was dialyzed (cutoff 3.5-kDa; Spectrum, Hous-
ton, TX, USA) extensively against distilled water. The sample 
was centrifuged, and the supernatant was then filtered (0.22 
μm pore; Millipore, Bedford, MA, USA), lyophilized, and kept at 
-70°C before use. Key steps for the preparation of pollen aller-
gen extracts are summarized in Fig. 1. Commercial skin test re-
agent of H. japonicus was obtained from Allergopharma (Rein-
beck, Germany). A commercial mugwort pollen extract (1:20 
w/v; Hollister-Stier Laboratories, Spokane, WA, USA) was also 
purchased for in vitro comparison.
Subjects
The study was approved by the Institutional Review Board (4-
2009-0717). Informed consent was obtained before skin testing 
and blood drawing. Twenty two Japanese hop-allergic subjects 
(age range, 19 to 62 years; mean 39 years) and 20 mugwort-aller-
gic patients who visited the Allergy-Asthma Center at Severance 
                    Fig. 1. Pollen allergen extraction procedure. Key steps and key points are summarized.
Consultation to taxonomists for the species identification
Elimination of lipid constituents
Dehydration to facilitate the allergen extraction
Selection of appropriate buffer to maximize the allergen content
Elimination of low molecular weight components including haptens and salts
Filter-sterilization
Suitable form for the long storage
Estimation of protein concentration, major allergen content, and allergen potency
Annotation of lot number and compilation of data sheet
Steps
Defatting
Freeze-dry
Dialysis
Filtration
Quality control
Allergen extraction
Raw material
(collection, culture, or purchase)
Freeze-dry and storage
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Hospital in Seoul, Korea were enrolled for the in vivo standard-
ization of Japanese hop and mugwort pollen extracts (Table 1 
and 2). Inclusion criteria for the in vivo standardization were 1) 
apparent symptoms of rhinitis, such as rhinorrhea, sneezing, 
coughing, and itching of the eyes and nose during the pollen sea-
son and 2) a more than twofold increase in the wheal size of pol-
len extracts compared to histamine controls in the skin prick test. 
Intradermal skin tests were performed on the enrolled subjects.
SDS-PAGE and IgE immunoblot analysis
The lyophilized extract was reconstituted in distilled water or 
buffer, and the protein concentration was determined via Brad-
ford assay (Bio-Rad, Hercules, CA, USA). Thereafter, the extract 
was aliquoted and stored at -70°C until use. The protein profile 
and IgE reactive components were examined by performing so-
dium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotting. Lyophilized extracts were reconsti-
tuted in a solution containing 0.9% NaCl and 0.03% human 
serum albumin. Extracts (30 μg of protein each) were separated 
onto 15% gels under reducing conditions. Proteins were stained 
with Coomassie blue or transferred onto polyvinylidene difluo-
ride (PVDF) membrane (0.45 μm, Millipore). Then, the mem-
brane was incubated with 1:4 diluted sera (pooled serum from 
eight subjects or healthy controls). IgE antibodies were probed 
with alkaline phosphate-conjugated goat anti-human IgE 
(1:1000; Sigma-Aldrich, St. Louis, MO, USA) for 1 hour, and the 
color was developed using nitro blue tetrazolium and 5-bromo-
4-chloro-3-indolyl-phosphate (Promega, Madison, WI, USA).
Evaluation of allergen potency via quantitative  
intradermal skin test
Procedure for the determination of allergen potency via intra-
dermal skin test is illustrated in Fig. 2. Intradermal skin tests 
were performed to determine the potency BAU of the extract.20 
Table 1. Clinical Features of the Enrolled Japanese Hop-Allergic Subjects
Subject Gender/age D50 BAU Symptom/diagnosis
Sensitization profile
(ImmunoCAP or skin prick test)
sIgE to w22 
(class)
Total IgE
HJ-001 F/57 13.60 64439.4 AR, AS d2, w22 >100 (6) ND
HJ-002 F/54 ND ND AR, AS, CC, UT d2, e5, w22 >100 (6) ND
HJ-003 F/44 ND ND AR, AS d2, e1, w7, w22 95.5 (5) 474
HJ-004 F/57 15.00 300000 AR d2, e5, w22, t3, t7 35.8 (5) ND
HJ-005 F/51 15.00 300000 AC, AR, AS, OAS d2, i6, e82, m5, t2, t3, t5, t7, w1, w7, w12, w22 ND 330
HJ-006 M/27 15.00 300000 AE, OAS, UT d2, w22, t2, t3, t5, t7, e1, w22 66.4 (5) 335
HJ-007 F/25 13.20 41524.36 AC, AR w1, w6, w7, w22 42.6 (4) 99.6
HJ-008 M/29 13.90 89595.85 AC, AD, AR d2, i6, w22 20.9 (4) 192
HJ-009 M/50 12.30 15448.77 AC, AR w1, w22 31.4 (4) ND
HJ-010 M/59 14.35 146890.1 AR w6, w7, w22, t2, t3, t7 16.9 (3) ND
HJ-011 M/26 14.6 193318.2 AR d2, w6, w22 2.06 (2) ND
HJ-012 F/54 ND ND AR w9, w22, e6, e82 ND ND
HJ-013 F/29 17.2 3363474 AC, AD, CD, AR d2, e1, e5, m3, m81, w1, w22, t3, t7 56.3 (5) 2131
HJ-014 F/31 14.6 373719.3 AC, AR
w1, w6, w8, w9, w10, w22, g2, g3, g4, g5, g6, t2, 
t3, t7, t8, t10, t11, t12, t13, t15, t19, t213
ND ND
HJ-015 M/50 16.3 1251350 AS, AR d2, w22, t3, t7 13.9 (3) ND
HJ-016 M/19 14.8 240822.5 AR, AC, OAS d1, d2, w6, w22, g6, t3, t7 4.58 (3) 968
HJ-017 M/19 ND ND AR, AC
d1, d2, m1, w1, d5, w9, w10, w19, w22, g2, 
g3, g5, g6, t2, t3, t7, t8, t10, t11, t12, t15, 
t17, t19, t70, t213
ND ND
HJ-018 M/23 ND ND AR w5, w8, w19, w22 ND ND
HJ-019 M/37 ND ND AR, AC, UT d1, d2, e2, w22 19.2 (4) ND
HJ-020 F/31 14.6 193318.2 AR, AS d1, d2, w22 5.80 (3) 99.3
HJ-021 F/66 ND ND AR, AS d1, d2, w1, w6, w22 8.74 (3) 38.4
HJ-022 F/29 12.4 17242.73 AR, AS, CC, UT d1, d2, d72, e2, e5, w9, w22, t8, t10, t12, tx ND ND
Mean 14.4 459409.5
AC, allergic conjunctivitis; AD, atopic dermatitis; AE, angioedema; AR, allergic rhinitis; AS, asthma; CC, chronic cough; CD, contact dermatitis; OAS, oral allergy 
syndrome; UT, urticaria; BAU, bioequivalent allergen unit; IgE, immunoglobulin E.
d1, Dermatophagoides pteronyssinus; d2, D. farinae; d72, Tyrophagus putrescentiae; i6, German cockroach; e2, dog hair; e5, dog dander; e6, Guinea pig epitheli-
um; e82, rabbit epithelium; m3, Aspergilus fumigates; m5, Candida albicans; w1, ragweed; w6, mugwort; w7, Chrysanthemum leucanthemum; w8, dandelion; 
w9, plantain; w10, goosefoot; w12, goldenrod; w22, Japanese hop; wx, weed mix; g2, Bermuda grass; g3, cocksfoot; g4, meadow fescue; g5, rye-grass; g6, tim-
othy grass; t2, alder; t3, common silver birch; t5, beech; t7, white oak; t8, elm; t10, walnut; t11, platanus; t12, willow; t13, mulberry; t15, white ash; t17, Japa-
nese cedar; t19, acacia; t213, pine; tx, tree mix.
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Briefly, injections were made superficially with 50 μL of serial 
threefold dilutions of the extracts in 0.9% NaCl, 0.4% phenol, 
and 0.03% human serum albumin solution. At 15 minutes, the 
sum of the longest and midpoint orthogonal diameters of ery-
thema (∑E) in millimeters was recorded. The best-fit linear re-
gression lines of the mean of triplicate ∑E vs. log3 dose were cal-
culated for each individual tested in order to analyze the potency 
of the extract. An extract concentration with an erythema di-
ameter sum of 50 mm of the 14th threefold dilution (∑ED50) 
was arbitrarily designated as 100000 BAU/mL.
RESULTS
Protein analysis of allergen extracts
Both commercial and collected Japanese hop pollen extracts 
showed strong bands of 11- and 15-kDa proteins on SDS-PAGE 
analysis despite several differences for proteins of higher mo-
Table 2. Clinical Features of Enrolled Mugwort-Allergic Subjects
Subjects Gender/age D50 BAU Symptom/diagnosis
Sensitization profile
(ImmunoCAP or skin prick test) 
sIgE to w6 
(class)
Total IgE
AV-001 F/28 11.7 30077.65 AR
t2, t3, t7, t8, t10, t11, t12, t70, t14, t16, g8, w1, w8, 
w10, w22, w21, d72, d1, d2, e1, e5
ND ND
AV-002 M/45 10.3 7417.058 AR
t7, t11, t12, t70, w1, w6, w7, w8, w10, 
w12, m1, d1, i6
8.45 (3) ND
AV-003 F/43 15 815484.5 AR, AC w1, w6, w8 ND ND
AV-004 M/45 13.6 201096 AR, AS, drug allergy
t5, t7, t8, t10, t11, t19, t16, g8, g5, g12, g6, w1, w6, 
w7, w8, w10, w12, w9, w22, m1, m2, m5, d72, d1, 
d2, e1, e5, e3, e84, e73, i206
5.65 (3) ND
AV-005 M/20 12 40600.58 AR t2, t3, t5, t7, w1, w6, w7, w8, w12, m3, d72, d1, d2 0.61 (1) 284
AV-006 M/52 ND ND AR, OAS
t1, t2, t3, t7, t8, t10, t11, t12, t70, t11, t16, 
t6, g6, w1, w6, w8, w10, w22, m1, e1, e5, e3
ND ND
AV-007 M/46 14.9 737880.9 AR
t2, t3, t7, t8, t10, t12, t70, t11, t15, t16, 
w6, w8, w9, w22, m1
ND ND
AV-008 F/58 ND ND AR, AC t3, w1, w6, w22, d2, e5 25.5 (4) 784
AV-009 F/46 12 40600.58 AR, AS, drug allergy w1, w6, w8 ND ND
AV-010 M/19 14 300000 AR, AC, OAS
t1, t2, t3, t7, t8, t10, t70, t15, t19, t16, g8, g2, g3, 
g6, w6, w8, w22, d72, d1, d2, e1, e5, i6, i206
4.81 (3) 968
AV-011 M/34 14.9 737880.9 AR, AC
t1, t2, t3, t7, t8, t10, t11, t12, t70, t11, t15, 
t19, t16, t16, t6, g8, g2, g3, g5, g6, w1, w6, 
w10, w9, w22, e1, e5, f11, d2
ND ND
AV-012 M/19 ND ND AR, AC
t1, t2, t3, t7, t8, t10, t11, t12, t70, t11, t15, t19, 
t14, t16, t6, g8, g2, g3, g5, g6, w1, w6, w10, w9, 
w22, w21, m1, m2, d1, d2, e3, i206, f11, f4
ND ND
AV-013 F/53 13.3 148975.6 AR, AS, drug allergy
t10, t16, g6, w6, w8, w22, w21, m1, m2, m3, 
m5, m6, d72, d1, d2, e1, e5, e3, e4, e6, i6, i206
3.66 (3) ND
AV-014 M/41 14.4 447547.4 AR t1, g6, w6, w8, d1 ND ND
AV-015 F/37 14.6 546635.6 AR t10, w1, w6, w8, w10, m2, d1, d2, e5 ND ND
AV-016 M/23 ND ND AR w6, w8, w22, w21, m1 ND ND
AV-017 F/20 ND ND
AR, chronic urticaria, 
drug allergy
w6, w8 ND ND
AV-018 M/42 15.6 1485910 AR t1, g2, w1, w6, w8, w10, w22, d72, d1, d2, i6 ND ND
AV-019 F/37 12.6 73979.09 AR w1, w6, w8, w10, w9, d1, d2, e1, e5, i6 ND ND
AV-020 M/38 13 110363.8 AR, AS, AD t6, w6, w8, d1, d2, e1, e5 ND ND
Mean 13.55 60691.3
AR, allergic rhinitis; AS, asthma; AC, allergic conjunctivitis; OAS, oral allergy syndrome; BAU, bioequivalent allergen unit; IgE, immunoglobulin E.
t1, acer; t2, alder; t3, birch; t5, beech; t7, oak; t8, elm; t10, walnut tree; t11, elder; t12, willow; t14, poplar; t16, pine; t19, acacia; t70, mulberry; g2, Bermuda 
grass; g3, cocksfoot; g5, rye-grass; g6, timothy grass; g8, meadow grass; g12, cultivated rye; w1, ragweed; w6, mugwort; w8, dandelion; w9, plantain; w10, 
goosefoot; w21, wall pellitory; w22, Japanese hop; m1, Penicillium; m2, Cladosporium; m3, Aspergilus; m5, Candia; m6, Alternaria; d1, Dermatophagodes ptero-
nyssinus; d2, D. farinae; d72, Tyrophagus putrescentiae; e1, cat dander; e3, horse dander; e4, cow dander; e5, dog dander; e6, Guinea pig epithelium; e73, rat 
epithelium; e84, hamster epithelium; i6, German cockroach; i206, American cockroach; f4, wheat; f11, buckwheat.
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lecular weight (20–60-kDa) (Fig. 3). An allergen of 11-kDa from 
both commercial and collected extracts exhibited the strongest 
IgE reactivity in IgE immunoblot analysis. A protein of 15-kDa 
from our collected extract showed somewhat stronger IgE reac-
tivity compared to that of the commercial extract.
The pattern of protein bands on SDS-PAGE of our mugwort 
extract was similar to that of Hollister-Stier mugwort extract (Fig. 
4A). A stronger band of about 28-kDa was shown from the com-
mercial extract. However, a thicker band of 12-kDa protein was 
observed from our extract (Fig. 4B). In IgE immunoblotting, 
strong IgE reactivity was also detected at around 28-kDa from 
both extracts. However, a stronger IgE reaction to approximate-
ly 12- and 20-kDa allergens was shown only from our extract.
Comparison of allergic activity of standardized  
Japanese hop pollen extract with commercial skin 
prick test extract 
The biologic activity of our prepared extract was 88983.6 BAU/
mg. Activity of the prepared skin prick extract was compared with 
that of commercial skin test reagent via inhibition ELISA (Fig. 5).
Commercial skin prick test reagent inhibited our extract to a 
maximum of 96.0%, while our extract inhibited 95.7%. Our ex-
tract was able to inhibit the commercial skin prick extract to a 
maximum of 94.7%, while the commercial extract inhibited 
95.2%. The allergic activities of both extracts were essentially in-
distinguishable.
Allergen potency of the prepared standardized  
Japanese hop pollen extract measured via  
quantitative intradermal skin test
Intradermal tests were performed using prepared standardized 
Japanese hop pollen extract on 15 patients who were highly 
A
B
C
Fig. 2. In vivo standardization. Serially diluted allergen extracts were in-
tradermally injected in subjects (A), and erythema size was measured af-
ter 15 to 20 minutes (B). The allergen potency was determined by calcu-
lating the dilution that induced an erythema diameter sum of 50 mm (C).
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Fig. 4. SDS-PAGE (A) and IgE immunoblot (B) analyses of mugwort ex-
tracts. M, molecular mass marker; YS, Yonsei extract; HS, Hollister-Stier 
extract; A, mugwort-sensitized sera; B, non-atopic sera; C, buffer control. 
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Fig. 3. SDS-PAGE (A) and IgE immunoblot (B) analyses of Japanese hop 
pollen extracts. Twenty microlligrams of proteins were separated on 15% 
polyacrylamide gel under reducing conditions. IgE reactive proteins were 
probed with a pooled serum of Japanese hop-sensitized patients. M, mo-
lecular weight standards; A, commercial (allergopharma) Japanese hop 
extract; Y, our (Yonsei) collected Japanese hop extract. SDS-PAGE, sodium 
dodecyl sulfate polyacrylamide gel electrophoresis; IgE, immunoglobulin E.
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sensitized to H. japonicus. ∑ED50 was calculated to be a 14.4th 
dilution. Therefore, allergenic activity of the prepared standard-
ized extract was 172572 BAU/mL (90827.4 BAU/mg) (Table 1).
Allergen potency of mugwort pollen extract
The protein concentration of our mugwort extract was 1.105 
mg/mL, whereas that of Hollister-Stier extract was 0.22 mg/mL 
as determined via Bradford assay. ImmunoCAP inhibition was 
performed to compare the allergen potencies of the extracts. 
Hollister-Stier extract was able to inhibit IgE reactivity to a maxi-
mum of 82.0%, while our extract inhibited IgE reactivity up to 
84.5% (Fig. 6). Inhibition curves from these two extracts were not 
parallel at the inhibitor concentration from about 0.02 to 1.25 
μg/mL. Fifty inhibitory concentrations were determined to 0.97 
μg/mL for Hollister-Stier extract and 0.55 μg/mL for our extract.
The average ∑ED50 of investigated reference material deter-
mined from 15 highly allergic subjects was 13.6, and the aller-
gen potency of the mugwort reference material was calculated 
to be 60691 BAU/mL (Table 2). Therefore, the allergen potency 
of Hollister-Stier extract should be about 34412 BAU/mg.
DISCUSSION
Standardization of allergen extracts is essential for the develop-
ment of diagnostic and immunotherapeutic reagents. However, 
standardization of Japanese hop pollen extract has not been 
performed despite it being a major cause of autumn pollinosis 
in East Asia. Therefore, we produced reference material for Japa-
nese hop extract and compared its allergenicity with a commer-
cial extract, which is commonly used for diagnosis. Furthermore, 
potency of the allergen extract was determined via intradermal 
skin test for the first time. Commercial Japanese hop extract is 
provided in a PNU. One PNU is known to contain approximately 
0.06 μg of protein.21 In this study, reference material for Japanese 
hop extract was determined to have 90827.4 BAU/mg (equiva-
lent to 5.45 BAU/PNU if 1 PNU is 0.06 μg of protein) (Table 1), 
and commercial extract (its allergen potency was indistinguish-
able from our extract) is provided in a 5000 PNU/mL unit (Fig. 4). 
Consequently, it could be calculated that 1 PNU is equivalent to 
6.58 BAU.
Mugwort is a common cause of pollinosis in autumn. Howev-
er, non-standardized mugwort pollen extracts are still used for 
diagnosis and immunotherapy. In this study, allergen potency 
of the mugwort pollen extract, which was prepared in a stan-
dardized way was estimated via quantitative intradermal skin 
test and compared with a commercial extract.
Six allergens from mugwort have been described (www.aller-
gen.org): Art v 1, a defensin-like protein (28-kDa); Art v 2, patho-
genesis-related protein 1 (20-kDa); Art v 3, non-specific lipid 
transfer protein (12-kDa); Art v 4, profilin (14-kDa); Art v 5, pol-
calcin (10-kDa); and Art v 6, pectate lyase (44-kDa). In the ex-
tract, 28-kDa allergen, a putative Art v 1, exhibited strong IgE re-
activity in both extracts on IgE immunoblotting (Fig. 4). Differ-
ences in IgE reactivity to 12-kDa (a putative Art v 3) and 20-kDa 
(a putative Art v 2) proteins may reflect the different concentra-
tions of these allergens. Different allergen compositions also 
resulted in the unparalleled inhibition curve (Fig. 6). Quantifi-
cation of major allergen content is helpful for better standard-
ization of the allergen extracts.17 A major allergen was cloned, 
and monoclonal antibodies were developed for the quantifica-
Fig. 5. ELISA inhibition analysis of Japanese hop extracts. IgE reactivity to our (Yonsei) collected (A) and commercial (Allergopharma) (B) extracts was in-
hibited at a various concentrations. ELISA, enzyme-linked immunosorbent assay.
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tion of Art v 1.22,23 However, two-site ELISA kits for the quantifi-
cation of mugwort allergen are not commercially available.
In this study, the allergen potency of the standardized refer-
ence mugwort pollen extract was determined to be 60691 BAU/
mL and to include 54924 BAU/mg of protein, which could be 
translated as 3.295 BAU/PNU.21 The potency of the commercial 
extract for immunotherapy (1:20 w/v, Hollister Stier) was calcu-
lated to be 34412 BAU/mL based on 50% inhibitory concentra-
tions. The probable effective dose for the non-standardized 
mugwort pollen extracts was estimated to be 0.5 mL of 1:100 or 
1:200 w/v.10 Therefore, approximately 3400 to 6800 BAU could 
be an effective dose for immunotherapy. Further studies are 
necessary to determine the optimal dose for effective immuno-
therapy.
Quantification of major allergen content is important for the 
standardization of allergen extract. Major allergen concentra-
tions in the extract were found to be strongly correlated with the 
potency of the extract, though with significant differences in the 
major allergen concentration at equal allergen potency.17,24 Fur-
thermore, 5–20 μg of major allergen is thought to be adminis-
tered in a maintenance phase for effective immunotherapy. 
The concentration of the 15-kDa allergen, a putative profilin, 
was found to be different from those of the commercial and 
collected Japanese hop pollen extracts (Fig. 1). However, pro-
filin is not a major allergen, as noted in our previous report.19 
Thus, there is an urgent need to characterize the 11-kDa aller-
gen for better standardization of Japanese hop pollen extract.
The allergen extract produced in this study could be used as a 
reference material for standardization. Its allergen potency 
(unit) determined via quantitative intradermal skin test could 
also contribute to better standardization.9,25 The newly acquired 
data obtained via in vivo standardization of Japanese hop and 
mugwort pollen extract could be helpful for the development of 
diagnostics and immunotherapeutics, especially for Japanese 
hop allergy.
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